Sphera Funds Management LTD. acquired a new stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,243,039 shares of the company's stock, valued at approximately $6,377,000. Annexon makes up approximately 1.2% of Sphera Funds Management LTD.'s holdings, making the stock its 29th biggest position. Sphera Funds Management LTD. owned 1.17% of Annexon as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Annexon in the 4th quarter valued at $59,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Annexon in the 4th quarter valued at $77,000. E Fund Management Co. Ltd. raised its stake in shares of Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after buying an additional 4,086 shares in the last quarter. Forefront Analytics LLC raised its stake in shares of Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company's stock valued at $84,000 after buying an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Annexon in the 4th quarter valued at $98,000.
Wall Street Analysts Forecast Growth
ANNX has been the subject of a number of recent research reports. HC Wainwright dropped their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Needham & Company LLC dropped their price objective on shares of Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th.
View Our Latest Stock Analysis on ANNX
Annexon Trading Up 4.0%
Shares of Annexon stock traded up $0.08 during mid-day trading on Monday, reaching $2.09. 1,655,590 shares of the stock were exchanged, compared to its average volume of 1,782,885. The company has a market cap of $229.30 million, a price-to-earnings ratio of -1.99 and a beta of 1.24. The firm has a 50-day simple moving average of $1.90 and a 200 day simple moving average of $3.59. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). On average, research analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.
Annexon Profile
(
Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
